Novo Nordisk A/S (NONOF)

OTCMKTS · Delayed Price · Currency is USD
113.15
+1.15 (1.03%)
Oct 28, 2024, 4:00 PM EDT
22.32%
Market Cap 493.25B
Revenue (ttm) 37.07B
Net Income (ttm) 12.92B
Shares Out n/a
EPS (ttm) 2.89
PE Ratio n/a
Forward PE n/a
Dividend 0.52 (0.44%)
Ex-Dividend Date Aug 15, 2024
Volume 300
Open 112.00
Previous Close 112.00
Day's Range 112.00 - 113.15
52-Week Range 93.80 - 149.55
Beta 0.15
Analysts n/a
Price Target n/a
Earnings Date Nov 6, 2024

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1923
Employees 64,319
Stock Exchange OTCMKTS
Ticker Symbol NONOF
Full Company Profile

Financial Performance

In 2023, Novo Nordisk's revenue was 232.26 billion, an increase of 31.26% compared to the previous year's 176.95 billion. Earnings were 83.68 billion, an increase of 50.71%.

Financial numbers in DKK Financial Statements

News

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 28 October 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...

1 day ago - GlobeNewsWire

Kivu Bioscience Raises $92 Million Series A Led by Novo Holdings to Advance Next-Generation Antibody-Drug Conjugates

SAN FRANCISCO--(BUSINESS WIRE)--Kivu Bioscience Raises $92 Million Series A Led by Novo Holdings to Advance Next-Generation Antibody-Drug Conjugates.

1 day ago - Business Wire

Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1 Revolution?

Novo Nordisk dominates diabetes treatment and obesity care, but one clinical-stage pharma company could be the next breakout star.

2 days ago - The Motley Fool

This Is Huge News for Novo Nordisk (Hint: It Doesn't Involve Ozempic)

Novo Nordisk just released data from a clinical trial featuring its oral semaglutide treatment, Rybelsus.

3 days ago - The Motley Fool

Ozempic Can Potentially Cut Risk Of Alzheimer's Compared To Other Diabetic Medicines, Study Shows

Researchers at Case Western Reserve University School of Medicine have discovered that Novo Nordisk A/S’ (NYSE: NVO) semaglutide, an ingredient for a well-known diabetes and weight-loss drug, may red...

5 days ago - Benzinga

Novo Nordisk's semaglutide could also be effective against Alzheimer's

Study finds GLP-1 drugs like semaglutide may reduce Alzheimer's risk for diabetes patients. Read more here.

5 days ago - Seeking Alpha

Lilly to launch its obesity drug in Denmark, Novo Nordisk's home market

Lilly will launch its Mounjaro obesity drug in Denmark next week, the U.S. drugmaker said on Thursday, bringing competition to the home country of its biggest weight-loss rival, Danish pharmaceuticals...

5 days ago - Reuters

Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says

The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer's diagnosis in diabetes patients.

5 days ago - CNBC

Ozempic And Wegovy Maker Novo Nordisk Asks FDA To Halt Production Of Compounded Fat Loss Drugs Due To Their 'Inherent Complexity'

Novo Nordisk (NYSE: NVO) has appealed to the U.S. Food and Drug Administration (FDA) to halt the production of compounded versions of its drugs Wegovy and Ozempic by compounding pharmacies. These che...

6 days ago - Benzinga

Who Will Dominate the Future of Pharmaceutical Industries in 2030?

Dear reader, market forecasts for 2030 indicate a significanttransformation in the global pharmaceutical landscape, with several leading companies, including Novo Nordisk and Eli L...

6 days ago - Makkah News (صحيفة مكة)

Novo Nordisk asks FDA to block compounding pharmacies from making Ozempic copy-cats

Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own versions of the company’s popular weight loss drug Wegovy and diabetes treatmen...

6 days ago - The Hill

Nvidia Launches Danish Sovereign AI Supercomputer That Novo Nordisk Will Use

Pharmaceutical giant Novo Nordisk plans to use Denmark's first sovereign artificial intelligence supercomputer—powered by Nvidia technology—for drug discovery.

6 days ago - Investopedia

Healthy Returns: Weight loss, diabetes drugs may reduce alcohol and opioid use

GLP-1 drugs such as Novo Nordisk's Ozempic can cut drug and alcohol abuse by around half. Meanwhile, tech companies are talking the future of AI in health care.

6 days ago - CNBC

Novo Nordisk asks US to stop compounding pharmacies from making weight-loss drug copies

Novo Nordisk on Tuesday asked the U.S. Food and Drug Administration to ban compounding pharmacies from making copycat versions of its popular weight-loss and diabetes drugs, which it said were too com...

6 days ago - Reuters

Novo Nordisk's Death Cross: Is A Turnaround Coming For The Ozempic, Wegovy Maker?

Novo Nordisk A/S (NYSE: NVO) just hit a technical red flag — a Death Cross . Chart created using Benzinga Pro For those uninitiated, this bearish signal occurs when a stock's 50-day moving average dr...

6 days ago - Benzinga

Novo Nordisk's Death Cross: Is A Turnaround Coming For The Ozempic, Wegovy Maker?

Novo Nordisk A/S NVO just hit a technical red flag — a Death Cross.

6 days ago - Benzinga

Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies

The Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for those manufacturers to make safely.

6 days ago - CNBC

Thermo Fisher Scientific Sails Through Q3 With Mixed Earnings, CEO Says In Great Position To Deliver 2024 Objectives

On Wednesday, Thermo Fisher Scientific Inc. (NYSE: TMO) posted third-quarter revenue of $10.59 billion, almost flat year over year, marginally missing the consensus of $10.64 billion . Revenue growth,...

6 days ago - Benzinga

Danes to Use New Nvidia AI Supercomputer for Drug Discovery

Denmark unveiled an Nvidia-powered supercomputer that will be used by Novo Nordisk A/S and other Danish pharmaceutical companies as they seek novel drugs and smarter trial designs.

6 days ago - BNN Bloomberg

Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains?

Viking Therapeutics Inc. (NASDAQ: VKTX) is set to report its third-quarter earnings on Wednesday, after the market closes. The anticipation is palpable, especially as the stock has skyrocketed almost...

7 days ago - Benzinga

Dr. Scot Gottlieb on Novo Nodrisk's oral diabetes drug, future of weight-loss drugs

Former FDA Commissioner Dr. Scot Gottlieb joins 'Squawk Box' to discuss news of Novo Nordisk's oral diabetes drug cutting heart-related risks in patients, state of the weight-loss drugs market, and mo...

7 days ago - CNBC Television

Dr. Scot Gottlieb on Novo Nodrisk's oral diabetes drug, future of weight-loss drugs

Former FDA Commissioner Dr. Scot Gottlieb joins 'Squawk Box' to discuss news of Novo Nordisk's oral diabetes drug cutting heart-related risks in patients, state of the weight-loss drugs market, and mo...

7 days ago - CNBC

Eli Lilly Sues Some Vendors For Unauthorized Sale Of Fake Weight-Loss Drug

Eli Lilly And Co (NYSE: LLY) has reportedly sued some medical spas and online vendors for allegedly selling unauthorized versions of tirzepatide, the active ingredient in its weight-loss medication, ...

8 days ago - Benzinga